Our Board of Directors is comprised of seasoned industry leaders with a solid range of life science, technology and business expertise. The Board brings this experience and perspective to guide the success of IntegenX® products and business strategy.
Dr. David L. Barker currently serves on the Boards of Directors of ProteinSimple, BioNano Genomics, and AmideBio, and is Board Member and Chairman at Integrated Diagnostics and IntegenX, Inc. He is a scientific advisor to Illumina, Inc., where he was Vice President and Chief Scientific Officer from 2000 to 2007. He was previously on the Board of NextBio, which was acquired by Illumina in 2013. Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham.
In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University.
Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.
Dr. James C. Blair has been a Partner of Domain since its founding in 1985. Dr. Blair has over 40 years experience with venture and emerging growth companies. In the course of this experience, he has been involved in the creation and successful development at the Board level of over 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Dura Pharmaceuticals, GeneOhm Sciences, Molecular Dynamics, Nuvasive, Pharmion and Volcano. Present board memberships include Cadence Pharmaceuticals, Cell Biosciences, Clovis Oncology, Inc., CoDa Therapeutics, Five Prime Therapeutics, GenVault, Helixis, Meritage Pharma, IntegenX, NeuroPace, and Zogenix.
A former managing director of Rothschild Inc., Dr. Blair was directly involved at a senior level with Rothschild/New Court venture capital activities from 1978 to 1985. From 1969 to 1978, he was associated with F.S. Smithers and Co. and White, Weld and Co., two investment banking firms actively involved with new ventures and emerging growth companies. From 1961 to 1969, Dr. Blair was an engineering manager with RCA Corporation, during which time he received a David Sarnoff Fellowship.
Dr. Blair currently serves on the Board of Directors of the Prostate Cancer Foundation, and he is on the Advisory Boards of the Department of Molecular Biology at Princeton University, the Department of Biomedical Engineering at the University of Pennsylvania, the USC Stevens Institute for Innovation, and the Division of Chemistry and Chemical Engineering at the California Institute of Technology.
Dr. Blair received a B.S. in Engineering from Princeton University and both M.S.E. and Ph.D. degrees from the University of Pennsylvania.
Ron Eastman joined Essex Woodlands in the Palo Alto office in 2006 and is a Managing Director. Mr. Eastman has over 30 years of experience in building healthcare businesses. He has helped build three private healthcare companies—Geron, HCORP, and Rinat Neuroscience. Under his leadership, Geron grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. Most recently, at Rinat, a private biotech company spun out of Genentech with the support of Essex Woodlands in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer for $500M in 2006. Mr. Eastman began his career at American Cyanamid Company, where he spent 15 years managing various pharmaceutical products, divisions and subsidiaries in the U.S. and overseas.
Mr. Eastman holds a B.A. from Williams College and an M.B.A. from Columbia University.
Mr. Grever joined Qbase in early 2012 after serving 24 years with the FBI, where he held increasingly responsible leadership positions since starting as a Special Agent in 1988. In 2008, he was appointed as Executive Assistant Director of the FBI Science and Technology Branch (STB). In this key role, he was accountable for all forensic, biometric, and applied technology support to the U.S. law enforcement and intelligence communities delivered by the FBI Laboratory, Criminal Justice Information Services (CJIS), and Operational Technology Divisions. In 2007, Mr. Grever was selected as the deputy to the STB Executive Assistant Director, following his service as Deputy Assistant Director in charge of the STB’s Special Technologies and Applications Office, responsible for developing and delivering innovative technical and analytical tools and capabilities.
Mr. Grever earned a Bachelor of Science degree in Police Administration and Management from the University of Louisville, as well as a Master of Science degree in Computer Information Systems from Strayer University. He received a Presidential Meritorious Executive Rank Award in 2011 and the National Intelligence Distinguished Service Medal in 2012.
Stevan Jovanovich, Ph.D.
Co-Founder of IntegenX
Chief Technology Officer
Dr. Stevan Jovanovich is President and CEO of IntegenX, a company he co-founded in 2003 to better optimize sample preparation for the life sciences. At IntegenX he has been the Principal Investigator on over $10 M of grants and contracts focused on DNA sequencing, biodefense, and forensics. He currently leads a growing team of talented professionals dedicated to commercializing the technology.
Dr. Jovanovich is an internationally recognized expert in microfluidics and an experienced global commercial leader. Before co-founding IntegenX, Dr. Jovanovich was Vice President of Global Research at Amersham Biosciences where he led a team of 120 scientists and engineers and drove multiple business projects across six international sites.
Prior positions include Science Director at Amersham Biosciences, Manager of Advanced Research at Molecular Dynamics, Staff Scientist at Lawrence Berkeley National Laboratory, Director of Microbiology at AbTox Inc, and founder of Molecular Solutions.
Dr. Jovanovich has proven expertise in microbiology, molecular genetics, microbial physiology, object-oriented programming, robotics, genomics, systems biology, and instrument and systems development. He is author of over 20 papers and an inventor on over 20 US patents. He holds Bachelor of Science degrees in Physics and Life Sciences from MIT, and a Ph.D. in Microbiology from University of California at Davis.
André F. Marion retired from the Perkin-Elmer Corporation as President of the Applied Biosystems Division in 1995. Mr. Marion was the Chairman of the Board, Chief Executive Officer, and President of Applied Biosystems, Inc. at the time of its merger with Perkin-Elmer in 1993. As one of the founders of Applied Biosystems, Mr. Marion served as its Chairman of the Board from 1987, President and Chief Executive Officer from 1986, Chief Operating Officer from 1983 to 1986, and was Vice President of Engineering from the founding of the Company in 1981 until 1983. Prior to founding Applied Biosystems, Mr. Marion held various Research and Development managerial positions at Hewlett-Packard.
Mr. Marion currently serves on the board of directors of several private companies.
A native of France, he holds an engineering degree from the French Ecole Nationale Supérieures d’Ingénieurs Arts et Métiers in both mechanical and electronic engineering.
Benjamin Schapiro founded QuestMark Partners in 1998. Prior to QuestMark, Mr. Schapiro began his career in investment banking at Robert Garrett & Sons, which merged into Alex. Brown & Sons. Throughout his 32-year tenure, Mr. Schapiro’s efforts encompassed institutional, international and private client accounts, real estate finance, corporate finance, merger and acquisition transactions as well as public and private investing in emerging growth companies.
Mr. Schapiro currently is or has been a member or active observer on the boards of Align Technology (ALGN), AngioScore, Aspect Medical Systems (ASPM), eHealth (EHTH), Fortify Software (acquired by HP), GeneOhm Sciences (acquired by Becton Dickinson), GenVault (acquired by IntegenX), Hospital Partners of America, Kodiak Networks, Mformation, Nimblefish (acquired by RR Donnelley), Rhythm NewMedia, SeniorHealth, TissueLink Medical (now Salient Surgical Technologies, acquired by Medtronic), Vapotherm and Xirrus. He has served as chairman, vice chairman and trustee or board member of a number of endowment funds, charitable organizations and professionally managed portfolios.
Mr. Schapiro earned a degree in Economics from Randolph-Macon College.
Bob has nearly 30 years of commercial and operational experience, and holding leadership positions in life science and diagnostic companies for more than two decades. Most recently, he was Vice President and General Manager, Genomics for Agilent Technologies. Prior to joining Agilent in 2010, he was the Global Head of Clinical Biomarkers and Operations, and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc., a company he joined in 2006. While at Genentech, Bob held increasingly responsible positions including Senior Director, Development Sciences and Director Companion Diagnostics.
Prior to Genentech, he was the Executive Vice President and Chief Operating Officer of Arcturus Bioscience from 2003 to 2006. From 1997 to 2002, Bob held senior leadership positions with Accumetrics and previously held commercial positions with Biosite Diagnostics, Gen-Probe and Abbott Diagnostics. Bob holds a BS in Pharmacy from Temple University.
James N. Woody, M.D., Ph.D
General Partner at Latterell Venture Partners
Dr. Jim Woody joined Latterell Venture Partners in 2006 and is also Board Chairman of OncoMed Pharmaceuticals. Dr. Woody was formerly President of Roche Biosciences, where he had responsibility for bioscience research and development. Previously, Dr. Woody served as Chief Scientific Officer and Senior Vice President of R&D for Centocor, where he developed both Remicade and ReoPro, clinically important drugs based on monoclonal antibody technology.
Prior to Centocor, Dr. Woody served as Commanding Officer and Director, US Naval Medical Research and Development Command. He was responsible for the surveillance, detection, and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War, and was awarded the US Navy Legion of Merit for his service.
Dr. Woody holds an M.D. from Loma Linda University and a PhD. in Immunology from the University of London, England. He has authored or co-authored more than 140 publications.